Akademik Veri Yönetim Sistemi
Ankara Universitesi Eczacilik Fakultesi Dergisi, cilt.46, sa.1, ss.182-192, 2022 (Scopus)
© 2022 University of Ankara. All rights reserved.Objective: As a result of increased need of glucose, reprogramming the metabolic pathways related to respiration is a significant change in cancer cells which differs them from normal cells and this change is known as “Warburg Phenomenon” because firstly reported by Otto Warburg in 1920s. Increased glycolysis in cancer cells makes glycolysis pathway an important target for cancer tratment. Hexokinase (HK), first and one of the rate limiting steps of glycolitic pathway, is an important target through this perspective since the prominent phenotype in cancer cells is HK-II, this makes the development of new therapies against this isozyme possible. Using medicinal chemistry approaches new inhibitors can be designed by determining the heterocycles and functional groups providing selectivity against this isozyme. Result and Discussion: Selective therapies against HK-II are based on inhibition, regulation, and expression of this enzyme. Small molecules targeting HK-II provide a basis for developing novel molecules. The discovery of selective inhibitors of HK-II is a promising progress for using selective and wide spectrum agents against cancer in the future cancer therapy.